SRPT

Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference

[at noodls] – Webcast Accessible via Sarepta Therapeutics Website CAMBRIDGE, MA — (Marketwired) — 04/18/13 — Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]

Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

[at noodls] – Data to Be Presented at the Muscular Dystrophy Association Scientific Conference CAMBRIDGE, MA — (Marketwired) — 04/05/13 — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments

[at noodls] – Upcoming Meetings With FDA Will Determine Fastest Path to Pursue Eteplirsen Approval; Additional Drugs for Duchenne Muscular Dystrophy (DMD) Continue to Progress Through Preclinical Development; 2013 Financial … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]

Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference

[at noodls] – Webcast Accessible via Sarepta Therapeutics Website CAMBRIDGE, MA — (MARKETWIRE) — 02/04/13 — Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]

Statement From Sarepta Therapeutics on Stock Volatility

[at noodls] – CAMBRIDGE, MA — (MARKETWIRE) — 01/30/13 — Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today issued the following statement from Chris Garabedian, President … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]

PropThink: Can Patients Scoop Clinical Trial Results?

[ACN Newswire] – By Jason Napodano, CFAIn the age of the Internet and social media portals such as Facebook and Twitter, investors are turning more and more to non-conventional sources of information to gain an advantage … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboard […]